At the request of the Minister of Health Olivier Véran, the Economic Committee for Health Products (CEPS) conducted negotiations with the American laboratory Vertex on the price of two drugs (Kaftrio® and Symkevi®) prescribed against cystic fibrosis. The Minister of Health announced this weekend that the negotiation had just reached an agreement on the price, which will allow 100% reimbursement of these two treatments by Health Insurance.
The reimbursement of these drugs should be effective in the next few days, said the Minister. during the 9th Interviews of the cystic fibrosis organized by the Vaincrelamuco association.
A reimbursement agreement has been reached for #Symkevi® and #Kaftrio®!
Eventually, 5,000 eligible patients will be able to benefit from it!
A huge THANK YOU to @olivierveran and the @VertexPharma and to the 37,458 people who signed the petition! @A_GregLemarchalhttps://t.co/k9QjVeCLaT— Defeat Muco (@vaincrelamuco) June 28, 2021
An improvement over existing drugs
Kaftrio® and Symkevi®, prescribed in combination with the drug Kalydeco®, have been granted by the High Authority for Health (HAS) an improvement in the actual benefit (ASMR) of level II and III respectively in the therapeutic management of cystic fibrosis in children over 12 years old, adolescents and adults. Level II and III ASMRs attest to an additional gain in efficacy, quality of life and safety demonstrated in clinical trials from the point of view of patients or healthcare professionals, compared to existing drugs. Eventually, 5,000 patients will be able to benefit from these innovative treatments.
“This very concretely means that patients will benefit from innovative and effective treatments, giving them the best chance of quality of life and increased life expectancy,” the Minister of Health told the patient association, which s was widely mobilized for the Kaftrio to be present in French pharmacies, as it already is in Germany, Denmark, Ireland, Switzerland, Finland or Slovenia.
Read also :
- Cystic fibrosis: a cure may be hiding in starfish
- Cystic fibrosis: a trial to restore respiratory functions
- Cystic fibrosis: the functioning of bacteria elucidated
